Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ningxinbao is a traditional Chinese medicine (TCM) capsule developed and marketed by Sichuan Good Doctor Panxi Pharmaceutical. The active ingredient consists of a dry powder of mycelium obtained through the liquid submerged fermentation of *Cephalosporium sinensis*, a fungus of the ergot family isolated from fresh *Cordyceps*. It is primarily indicated for the treatment of various cardiac conditions, including arrhythmias, atrioventricular block, refractory bradyarrhythmia, and conduction block. The drug works by enhancing sinus rhythm, improving the conduction function of the sinus node and atrioventricular node, and supporting overall heart function. As a traditional Chinese medicine, it lacks a single specified molecular target and is approved for commercial use in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ningxinbao.